Category Archives: AstraZeneca Crestor $3B to $6B AHA JUPITER v. Vytorin/Z

Look for Crestor’s "Jupiter" to Rock Schering — on Sunday (and Monday, on the NYSE). . . .

I’ll have There now is much more here come Sunday, the 9th, but know now that Crestor is — acoording to many Wall Street analysts — widely expected to double its market share (~$3 billion per year in 2008, to ~$6 billion per year by 2012), as a result of the huge success of AstraZeneca’s “Jupiter” study.

And it is very likely to take almost all of that share from Schering — and Vytorin/Zetia.

More here, on Sunday — from Louisiana.